The Histamine H3 Receptor as a Therapeutic Drug Target for Metabolic Disorders: Status, Challenges and Opportunities

By  

Current Topics in Medicinal Chemistry, Vol. 11, Iss. 12, 2011-06 ,pp. : 1430-1446

Bentham Science Publishers

Access to resources Recommend Favorite

The Anandamide Degradation System as Potential Target for the Treatment of Central Nervous System Related Disorders

By  

Current Medicinal Chemistry - Central Nervous System Agents, Vol. 4, Iss. 3, 2004-09 ,pp. : 155-160

Bentham Science Publishers

Access to resources Recommend Favorite

Structural and functional characterization of gastric mucosa and central nervous system in histamine H 2 receptor-null mice

By Fukushima Y.   Shindo T.   Anai M.   Saitoh T.   Wang Y.   Fujishiro M.   Ohashi Y.   Ogihara T.   Inukai K.   Ono H.   Sakoda H.   Kurihara Y.   Honda M.   Shojima N.   Fukushima H.   Haraikawa-Onishi Y.   Katagiri H.   Shimizu Y.   Ichinose M.   Ishikawa T.   Omata M.   Nagai R.   Kurihara H.   Asano T.  

European Journal of Pharmacology, Vol. 468, Iss. 1, 2003-05 ,pp. : 47-58

Elsevier

Access to resources Recommend Favorite

Histamine H3 Receptor (H3R) Antagonists and Inverse Agonists in the Treatment of Sleep Disorders

By  

Current Pharmaceutical Design, Vol. 17, Iss. 15, 2011-05 ,pp. : 1426-1429

Bentham Science Publishers

Access to resources Recommend Favorite

The Insulin-like Growth Factor-1 Axis and its Potential as a Therapeutic Target in Central Nervous System (CNS) Disorders

By  

Central Nervous System Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Central Nervous System Agents), Vol. 9, Iss. 2, 2009-06 ,pp. : 95-109

Bentham Science Publishers

Access to resources Recommend Favorite